Clinical Trial Update: Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of memantine for social deficits in youth with autism spectrum disorders has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Nonverbal Learning Disability

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Autism, Autism Spectrum Disorder | Phase 3 | Status: TERMINATED